Temperature instability during neonatal transport is a recognised contributor to adverse outcomes in preterm and low birth weight infants. The HOTWHEELS protocol frames hypothermia as linked to increased risk of intraventricular haemorrhage (IVH), sepsis, and death in this population. Current transport temperature management practices are described as reactive and manually controlled. The trial aims to determine whether an automated, servo-controlled patient temperature management system provides superior thermal stability compared with standard care during transport.
HOTWHEELS is a prospective, randomised, superiority trial conducted by the Newborn Emergency Transport Service of Western Australia. The protocol describes random allocation of eligible infants to either servo-controlled thermoregulation or standard thermal care for the duration of transport to a receiving neonatal unit. The manuscript is presented as the trial protocol; no outcome data are reported in this document.
Infants eligible for inclusion are those with a gestational age of less than or equal to 34 weeks and/or a birth weight of 1500 g or less who require transport. The protocol specifies that these criteria determine enrolment into the trial, with transport events forming the intervention period. The protocol text does not report numbers enrolled, sample size calculations, or enrolment targets in the source provided.
Participants are randomised to either the servo-controlled patient temperature management system arm or to standard thermal care. The published protocol confirms randomisation but does not include further operational details in the provided source text (for example, block size, stratification factors, or allocation concealment procedures were not reported in the source excerpt).
The intervention arm uses an automated, servo-controlled temperature management device intended to maintain target body temperature during transport. The comparator is routine, manually controlled thermal care that represents current practice. The protocol positions the servo-controlled approach as proactive and automated, contrasting it with reactive manual adjustments used in standard care. Specific device model, temperature set points, stepwise nursing actions, or other procedural details beyond the general description were not reported in the source text.
The predefined primary outcome is the proportion of infants with a temperature between 36.5°C and 37.5°C on arrival at the receiving neonatal unit.
Secondary outcomes specified in the protocol include:
The trial protocol document is clear that these outcome measures will be used to compare thermal stability and clinically relevant adverse events between arms. The source does not present outcome data or statistical results.
Ethical approval for the HOTWHEELS trial has been obtained from the Child and Adolescent Health Service Human Research Ethics Committee (HREC; Reference: RGS0000006433). The protocol confirms that trial-related monitoring, audits, and regulatory inspections will be permitted, allowing authorised representatives access to source documents and medical records for oversight. The trial is registered with an ANZCTR identifier (ANZCTR12624000503527 / ACTRN12624000503527). The authors state that all relevant ethical guidelines were followed, participant consent processes were completed and archived, and relevant reporting checklists were used.
The manuscript is a trial protocol and contains no patient-level data. The authors declare the Perth Children’s Hospital Foundation as a funder (grant identifier reported in the source as 2024-10015). The authors declare no competing interests.
HOTWHEELS is described as the first randomised trial in neonatal transport to evaluate a servo-controlled temperature control system. The investigators state they expect the findings to inform standards of temperature control during transport for preterm and low birth weight infants, by demonstrating whether automated temperature management improves arrival temperatures and reduces hypothermia-associated adverse outcomes. The protocol document itself does not report trial results, sample size details, or timelines for completion in the provided excerpt.